详情

原文传递 Evaluating Transdermal Alcohol Measuring Devices. Final rept. 31 Aug 04-06 Feb 28.

题名：	Evaluating Transdermal Alcohol Measuring Devices. Final rept. 31 Aug 04-06 Feb 28.
作者：	Marques-P.R.; McKnight-A.S.
关键词：	Alcohol-; Measuring-instruments; *Detection-.;Test-equipment; Drinking-drivers; Alcohol-consumption; Monitoring-; Offenders-; Blood-alcohol-concentration; Laboratory-tests; Evaluation-; Vendors-; Field-tests; Statistical-data; Research-program.
摘要：	This report is an evaluation study of two types of transdermal devices that detect alcohol at the skin surface representing two types of electrochemical sensing technology. The AMS SCRAM (trademark) ankle device and the Giner WrisTAS (trademark) wrist devices were worn concurrently for the evaluation by 22 paid research subjects (15 males, 7 females), for a combined total of 96 weeks. Each subject participated in both laboratory drinking to .08 grams per deciliter (g/dL) BAC and normal drinking on their own. A total of 271 drinking episodes with BAC > .02 g/dL were logged: 60 were from laboratory dosing, and 211 were from self-dosed drinking. Both devices detected alcohol at the skin surface. The SCRAM (trademark) unit has security features and automated reporting protocols that make it suitable for the offender market, whereas the WrisTAS (Trademark) unit is a research prototype that has had trials as an aid to detection for alcohol treatment settings. Neither unit had false-positive problems when true BAC was <.02 g/dL. False negatives were defined as TAC (transdermal alcohol concentration) response <.02 g/dL when true BAC>.02 g/dL. Overall, the true-positive hit rate detected by WrisTAS (trademark) was 24 percent. The low detection rate for the WrisTAC (trademark) was largely due to those devices' erratic output or not recording during nearly 67 percent of all episodes. SCRAM (trademark) correctly detected 57 percent across all BAC events, with another 22 percent (total 79%) detected, but as <.02 g/dL. SCRAM (trademark) devices were more accurate earlier than later in the trials and may have had problems with water accumulation that reduced sensitivity. When subjects dosed themselves to BAC <.08 g/dL, SCRAM (trademark) correctly detected 88 percent of these events. The report summarizes comments from research subjects, offenders, and vendors who manage transdermal detection programs.
报告类型：	科技报告